Results for tag: "Vorinostat"

Vorinostat is a drug used to treat cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma. It is a histone deacetylase inhibitor, meaning it works by blocking the action of an enzyme that helps cancer cells grow and divide. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL in adults who have not responded to other therapies. It is also being studied for the treatment of other types of lymphoma, including Hodgkin lymphoma and diffuse large B-cell lymphoma. Vorinostat is marketed by Merck & Co. under the brand name Zolinza. Other companies involved in the market include Celgene Corporation, which markets the drug under the brand name Istodax, and Sun Pharmaceutical Industries, which markets the drug under the brand name Zorin. Show Less Read more